Aberdeen Group’s Voyager Therapeutics VYGR Stock Holding History

Aberdeen Group’s Portfolio VYGR Stock Details VYGR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-34,909	Closed	-$660K	–	917
2018 Q3	$660K	Buy	+34,909	New	+$670K	﹤0.01%	844

Other funds holding VYGR

TGI

TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

HCM

Highline Capital Management New York $53.5M AUM 21.72% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Aberdeen Group's VYGR Position: Q4 2018 in Review

Aberdeen Group sold out of Voyager Therapeutics (VYGR) in Q4 2018, closing a stake of 34,909 shares — an estimated $660K sold.

Aberdeen Group first reported a position in VYGR in Q3 2018 and held it in 1 quarter. The position peaked at $660K in Q3 2018. 116 funds tracked by Wall St. Rank hold VYGR as of Q4 2018.

Aberdeen Group reported no remaining Voyager Therapeutics position as of Q4 2018 after selling out during the quarter.
Aberdeen Group sold 34,909 Voyager Therapeutics shares in Q4 2018, an estimated $660K.
Aberdeen Group first reported a position in Voyager Therapeutics in Q3 2018 and held it in 1 quarter.
Aberdeen Group's Voyager Therapeutics position peaked at $660K in Q3 2018.
116 funds tracked by Wall St. Rank held Voyager Therapeutics as of Q4 2018.

Based on Aberdeen Group's 13F filing for Q4 2018, filed 12 Feb 2019.